INDICATION(S)
nab-P 1 G ( Table 1) is used for the treatment of locally advanced or metastatic pancreatic adenocarcinoma. [1] [2] [3] [4] 
DRUG PREPARATION
Follow institutional policies for preparation and dispensing of hazardous medications when dispensing nab-paclitaxel and gemcitabine. A. nab-paclitaxel 1. Use nab-paclitaxel powder for injection. 2. Reconstitute the lyophilized powder with 0.9% sodium chloride injection (NS) to a concentration of 5 mg/mL. a. To prevent foaming, avoid rapid injection of fluid or vigorous shaking of the vial. b. Allow the vial to sit for a minimum of 5 minutes to ensure proper wetting of the lyophilized cake. c. Gently swirl and/or invert the vial slowly until the particles are evenly dispersed.
3. Dispense in an empty, sterile intravenous (IV) bag. B. Gemcitabine 1. Use gemcitabine hydrochloride injection 38 mg/mL or powder for injection. 2. Reconstitute the lyophilized powder to a concentration of 38 mg/mL with NS, 5% dextrose in water (D5W), or sterile water for injection (SWFI). a. When reconstituted according to the manufacturer's recommendation, the final concentration is 38 mg/mL, not 40 mg/mL. b. Reconstitution at concentrations greater than 40 mg/mL may result in incomplete dissolution and should be avoided. 3. Dilute with 50 to 250 mL NS for infusion.
DRUG ADMINISTRATION
A. nab-paclitaxel 1. The manufacturer recommends that the drug be given as a 30-to 40-minute IV infusion. 5 2. Infusion over 30 minutes has been associated with grade 3 or 4 peripheral neuropathy. Administering the drug over 2 hours has been shown to decrease the average severity and grade $2 peripheral neuropathy without affecting survival.
B. Gemcitabine 1. In the studies reviewed, the drug was given as a 30-to 40-minute IV infusion. 2 2. Infusion times greater than 60 minutes have been associated with increased grade 3 or 4 hematologic toxicity due to accumulation of the active metabolite gemcitabine triphosphate. 7 
SUPPORTIVE CARE
A. Acute Emesis Prophylaxis: According to accepted models for predicting emetogenicity, the nab-P 1 G regimen has a low (10% to 30%) risk of causing nausea or vomiting. 8 In the studies reviewed, nausea or vomiting was reported in 67%, 2 nausea in 48%, 3 and vomiting in 36% of patients, 3 suggesting that the regimen is more emetogenic than predicted by the models. The studies reviewed reported grade 3 or 4 nausea in 2% of patients and grade 3 or 4 vomiting in 7% of patients. 3 Prophylactic antiemetic therapy with a serotonin antagonist is recommended, [8] [9] [10] but may not be required in all patients. One group suggests that the addition of a neurokinin (NK 1 ) antagonist may be appropriate in some patients. 8 One of the following regimens given 30 minutes prior to therapy is suggested: 1. Ondansetron 8 mg to 16 mg orally (PO), 6 dexamethasone 12 mg PO. 2. Granisetron 1 mg to 2 mg PO, 6 dexamethasone 12 mg PO. 3. Dolasetron 100 mg PO, 6 dexamethasone 12 mg PO. 4. Palonosetron 0.25 mg IV, 6 dexamethasone 12 mg PO. Prophylactic use of an NK 1 antagonist is recommended for moderately emetogenic regimens if the 2-drug combination was not effective in the previous treatment cycle. [8] [9] [10] One of the following regimens given 30 minutes prior to therapy is recommended: 12 mg, and aprepitant 125 mg PO. The antiemetic therapy should continue for at least 3 days. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, which makes a steroid, or steroid and dopamine antagonist combination, most appropriate for follow-up therapy. 11 One of the following regimens is recommended:
1. Dexamethasone 4 mg PO twice a day for 3 days, 6 metoclopramide 0.5 to 2 mg/kg PO every 4 to 6 hours, 6 diphenhydramine 25 to 50 mg PO every 6 hours if needed, starting on day 2 of nab-P 1 G. 2. Dexamethasone 4 mg PO twice a day for 3 days, 6 prochlorperazine 10 mg PO every 4 to 6 hours, 6 diphenhydramine 25 to 50 mg PO every 6 hours if needed, starting on day 2 of nab-P 1 G. 3. Dexamethasone 4 mg PO twice a day for 3 days, 6 promethazine 25 to 50 mg PO every 4 to 6 hours, 6 diphenhydramine 25 to 50 mg PO every 6 hours if needed, starting on day 2 of nab-P 1 G. If an NK 1 antagonist is used, one of the following regimens is recommended:
1. Dexamethasone 4 mg PO twice a day for 3 days, aprepitant 80 mg PO every morning for 2 days, 6 metoclopramide 0.5 to 2 mg/kg PO every 4 to 6 hours, 6 diphenhydramine 25 to 50 mg PO every 6 hours if needed, starting on day 2 of nab-P 1 G. 2. Dexamethasone 4 mg PO twice a day for 3 days, aprepitant 80 mg PO every morning for 2 days, 6 prochlorperazine 10 mg PO every 4 to 6 hours, 6 diphenhydramine 25 to 50 mg PO every 6 hours if needed, starting on day 2 of nab-P 1 G. 3. Dexamethasone 4 mg PO twice a day for 3 days, aprepitant 80 mg PO every morning for 2 days, 6 promethazine 25 to 50 mg PO every 4 to 6 hours, 6 diphenhydramine 25 to 50 mg PO every 6 hours if needed, starting on day 2 of nab-P 1 G. Patients who experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [8] [9] [10] 12 There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles or increasing the dose, even to very high doses, is effective. This approach is not recommended. hours if needed, 6 diphenhydramine 25 to 50 mg PO every 6 hours if needed. C. Hematopoietic Growth Factors: Accepted practice guidelines and pharmacoeconomic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSF) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSF should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSF is not recommended. 18 In the studies reviewed, febrile neutropenia was reported in 1% to 8% of patients. [2] [3] [4] Therefore, prophylactic use of CSF is not recommended. The incidence of grade 3 or 4 neutropenia was in 17% to 73% of patients, so prophylactic use of CSF may be advisable in some patients.
2-4 CSF may be considered if a patient experiences febrile neutropenia or grade 4 neutropenia in a prior cycle of nab-P 1 G.
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:/ ctep.info.nih.gov). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but they make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Dermatologic: Alopecia (grade 1 or 2) 58%, 2 (all grades) 50%. ; febrile neutropenia (grade 3 or 4) 2% to 8%, 2-3 (all grades) 3% 4 ; leukopenia (grade 1 or 2) 34%, 3 (grade 3 or 4) 31% to 55% 3, 4 ; neutropenia (grade 1 or 2) 16% to 58%, 2,3 (grade 3 or 4) 17% to 73% [2] [3] [4] ; thrombocytopenia (grade 1 or 2) 17% to 61%, 2,3 (grade 3 or 4) 8% to 27%. 
